(Q24239922)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Fluticasone at different doses for chronic asthma in adults and children

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Fluticasone versus placebo for chronic asthma in adults and children

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Ciclesonide versus placebo for chronic asthma in adults and children

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Beclomethasone versus placebo for chronic asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Meta-analysis in clinical trials

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Delivered by the Diskustrade mark or Pressurised Metered-Dose Inhaler in Children with Asthma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Acute asthma intervention: insights from the STAY study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Canadian Pediatric Asthma Consensus guidelines, 2003 (updated to December 2004): introduction.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Maintenance asthma treatment with fluticasone/salmeterol combination via Diskus: effect on outcomes in inner-city children enrolled in TennCare

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Efficacy and tolerability of formoterol Turbuhaler in children.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Effect of long‐acting β2 agonists on exacerbation rates of asthma in children

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Beclomethasone for asthma in children: effects on linear growth

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Salmeterol xinafoate in children on high dose inhaled steroids

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected].

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Formoterol used as needed in patients with intermittent or mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

A population-based evaluation of a regional asthma education centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Mucociliary clearance in patients with chronic asthma: effects of beta agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Fixed and adjustable dose asthma action plans based on combination therapy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Traditional and patient-centred outcomes with three classes of asthma medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Benefit from anti-inflammatory treatment during clinical remission of atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: A randomized controlled trial in childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007949

Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Montelukast versus formoterol as second-line therapy in asthmatic children exposed to relevant allergens

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

The quality of life of the asthmatic child caregiver

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167878

Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group

29 November 2018

1 reference

12 December 2020

A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma

1 reference

12 December 2020

Randomized comparison of strategies for reducing treatment in mild persistent asthma

1 reference

12 December 2020

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

12 December 2020

Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide

1 reference

12 December 2020

Improving asthma treatment in a managed care population

1 reference

12 December 2020

A randomized controlled trial of an asthma clinical pathway for children in general practice

1 reference

12 December 2020

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids

1 reference

12 December 2020

Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial

1 reference

12 December 2020

Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma

1 reference

12 December 2020